| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/25/2013 | US20130101569 Hair growth stimulant |
| 04/25/2013 | US20130101565 Use of carbonic anhydrase ii for producing a drug |
| 04/25/2013 | US20130101554 Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis |
| 04/25/2013 | US20130101553 Inducing inactivation of fibrogenic myofibroblasts |
| 04/25/2013 | US20130101535 Aldehyde dehydrogenase inhibitors as novel depigmenting agents |
| 04/25/2013 | US20130101533 Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| 04/25/2013 | US20130101527 Methods, compounds and pharmaceutical compositions for treating neurological disorders |
| 04/25/2013 | US20130101524 Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery |
| 04/25/2013 | US20130101514 Compositions and methods for treating nephropathy |
| 04/25/2013 | US20130101510 Methods of treating parkinson's disease using viral vectors |
| 04/25/2013 | US20130101507 Treatment of Renal Cell Carcinoma |
| 04/25/2013 | US20130101506 Compositions comprising nucleic acid aptamers |
| 04/25/2013 | US20130098797 Two phase pharmaceutical delivery system |
| 04/25/2013 | US20130098377 Excipients for nicotine-containing therapeutic compositions |
| 04/25/2013 | US20130098357 Cerivastatin to treat pulmonary disorders |
| 04/25/2013 | US20130097969 Process to improve stability of a pharmaceutical composition |
| 04/25/2013 | DE112011101605T5 Pharmazeutische Zusammensetzung umfassend Hydromorphon und Naloxon A pharmaceutical composition comprising hydromorphone and naloxone |
| 04/25/2013 | DE102012004736A1 New 4-amino-3-phenylamino-6-phenylpyrazolo(3,4-d)pyrimidine derivatives useful as a medicament for prophylactic- or therapeutic treatment of viral infections, preferably picornavirus infections and rhinovirus infections |
| 04/25/2013 | DE102011122250A1 Multiphase system, useful e.g. to treat vitamin deficiency, comprises two different phases/layers comprising first phase/layer of active component comprising iron(II) compound, and second phase/layer of active component comprising vitamin |
| 04/25/2013 | CA2856703A1 Opsin-binding ligands, compositions and methods of use |
| 04/25/2013 | CA2853469A1 Compounds that modulate intracellular calcium |
| 04/25/2013 | CA2853084A1 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| 04/25/2013 | CA2852968A1 Pharmaceutical compositions of resveratrol |
| 04/25/2013 | CA2852939A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| 04/25/2013 | CA2852937A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| 04/25/2013 | CA2852936A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| 04/25/2013 | CA2852921A1 Treatment of cancer with tor kinase inhibitors |
| 04/25/2013 | CA2852917A1 Amine cationic lipids and uses thereof |
| 04/25/2013 | CA2852914A1 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
| 04/25/2013 | CA2852848A1 Acrylic polymer formulations |
| 04/25/2013 | CA2852843A1 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| 04/25/2013 | CA2852830A1 Acid addition salts of bosentan |
| 04/25/2013 | CA2852802A1 Glucagon binding nucleic acids |
| 04/25/2013 | CA2852777A1 Lyophilized liposomes |
| 04/25/2013 | CA2852750A1 Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| 04/25/2013 | CA2852723A1 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 04/25/2013 | CA2852685A1 Inhibitors of arginase and their therapeutic applications |
| 04/25/2013 | CA2852682A1 Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| 04/25/2013 | CA2852622A1 Acid addition salts of 5.alpha.-hydroxy-6.beta.-[2-(1h-imidazol-4-yl)ethylamino]cholestan-3.beta.-ol |
| 04/25/2013 | CA2852618A1 Pharmaceutical composition |
| 04/25/2013 | CA2852615A1 Novel substituted imidazopyrimidines as gpbar1 receptor modulators |
| 04/25/2013 | CA2852613A1 Paste comprising non-steroidal anti-inflammatory |
| 04/25/2013 | CA2852607A1 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones |
| 04/25/2013 | CA2852518A1 Method for inhibition of deubiquitinating activity |
| 04/25/2013 | CA2852425A1 2-pyridyloxy-4-nitrile orexin receptor antagonists |
| 04/25/2013 | CA2852417A1 Sustained-release preparation |
| 04/25/2013 | CA2852395A1 Compositions comprising ascorbic acid and an imaging agent and related methods |
| 04/25/2013 | CA2852368A1 Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| 04/25/2013 | CA2852268A1 Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| 04/25/2013 | CA2852214A1 Anti-diabetic aminosteroid derivatives |
| 04/25/2013 | CA2852142A1 Dosage regimen for an s1p receptor modulator or agonist |
| 04/25/2013 | CA2852039A1 New salt and medical use |
| 04/25/2013 | CA2851999A1 Solution for oral administration |
| 04/25/2013 | CA2851808A1 Use of inhibitors of bruton's tyrosine kinase (btk) |
| 04/25/2013 | CA2851754A1 Use of melatonin for treating and/or preventing mucositis |
| 04/25/2013 | CA2851640A1 Pyridopyrimidinone inhibitors of kinases |
| 04/25/2013 | CA2851589A1 Bicyclic heterocyclic compound |
| 04/25/2013 | CA2851412A1 Use of aminoacetonitrile derivatives against endoparasites |
| 04/25/2013 | CA2851396A1 Novel phenicol antibacterials |
| 04/25/2013 | CA2851275A1 2-methylene-vitamin d analogs and their uses |
| 04/25/2013 | CA2850987A1 Substituted biaryl alkyl amides |
| 04/25/2013 | CA2850441A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone |
| 04/25/2013 | CA2850277A1 Method for treating capillary hemangiomas |
| 04/25/2013 | CA2850273A1 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
| 04/25/2013 | CA2849564A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| 04/25/2013 | CA2838646A1 Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer |
| 04/24/2013 | EP2584048A1 Compositions and methods for inhibiting expression of the PCSK9 gene |
| 04/24/2013 | EP2584047A1 Compositions and methods for inhibiting expression of the PCSK9 gene |
| 04/24/2013 | EP2584041A1 Composition for preventing or treating diabetes comprising nad glycohydrolase inhibitor as active ingredient |
| 04/24/2013 | EP2584040A1 Compounds for treatment of ischemic injury |
| 04/24/2013 | EP2583977A1 Retinol-modified collagen, method for producing same, and external composition for skin containing same |
| 04/24/2013 | EP2583972A1 Therapeutic agent for inflammatory diseases containing adenosine n1-oxide as active ingredient |
| 04/24/2013 | EP2583970A1 Certain chemical entities, compositions and methods comprising imidazopyrimidines |
| 04/24/2013 | EP2583969A2 Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients |
| 04/24/2013 | EP2583968A1 Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses |
| 04/24/2013 | EP2583967A1 Crystal of amide compound |
| 04/24/2013 | EP2583966A2 Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases |
| 04/24/2013 | EP2583965A1 Heterocyclic ring compound |
| 04/24/2013 | EP2583964A1 Novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid |
| 04/24/2013 | EP2583963A1 Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
| 04/24/2013 | EP2583962A2 Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient |
| 04/24/2013 | EP2583720A1 Oxazolopyrimidines as Edg-1 receptor agonists |
| 04/24/2013 | EP2583698A1 Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
| 04/24/2013 | EP2583692A1 Inhibitor of expression of dominant allele |
| 04/24/2013 | EP2583691A1 Agent for treating renal fibrosis |
| 04/24/2013 | EP2583682A1 Antioxidant composition |
| 04/24/2013 | EP2583681A1 Oral veterinary composition for salmonids, comprising 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide and use thereof for the treatment of infectious salmon anaemia (isa) in salmonids |
| 04/24/2013 | EP2583680A2 Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| 04/24/2013 | EP2583679A1 Methods and compositions for intraocular administration to treat ocular conditions |
| 04/24/2013 | EP2583678A2 Small molecule immunopotentiators and assays for their detection |
| 04/24/2013 | EP2583677A2 Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| 04/24/2013 | EP2583676A1 Oleocanthal for treating pain |
| 04/24/2013 | EP2583675A1 Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| 04/24/2013 | EP2583674A2 Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day |
| 04/24/2013 | EP2583673A1 Coating of cetyl myristate and/or cetyl palmitate particles |
| 04/24/2013 | EP2583670A1 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| 04/24/2013 | EP2583669A1 Taste-masked orally disintegrating tablets of memantine hydrochloride |
| 04/24/2013 | EP2583668A1 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| 04/24/2013 | EP2583662A1 Composition comprising a meroterpen to manage oily skin with tendency to develop acne |
| 04/24/2013 | EP2582832A1 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders |